| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.31B | 6.21B | 5.95B | 5.67B | 4.86B | 4.45B |
| Gross Profit | 5.27B | 5.20B | 4.98B | 4.75B | 4.07B | 3.70B |
| EBITDA | 1.94B | 1.92B | 1.81B | 1.94B | 1.61B | 1.29B |
| Net Income | 1.14B | 1.20B | 1.05B | 931.50M | 773.70M | 491.00M |
Balance Sheet | ||||||
| Total Assets | 14.42B | 15.55B | 14.62B | 14.26B | 14.22B | 12.96B |
| Cash, Cash Equivalents and Short-Term Investments | 4.08B | 3.95B | 3.57B | 2.77B | 2.98B | 2.15B |
| Total Debt | 2.58B | 3.06B | 3.60B | 3.58B | 4.47B | 4.83B |
| Total Liabilities | 6.22B | 6.47B | 6.78B | 6.94B | 8.01B | 7.86B |
| Stockholders Equity | 8.18B | 9.07B | 7.83B | 7.31B | 6.20B | 5.06B |
Cash Flow | ||||||
| Free Cash Flow | 1.50B | 1.47B | 1.42B | 1.39B | 1.51B | 1.11B |
| Operating Cash Flow | 1.68B | 1.66B | 1.57B | 1.53B | 1.61B | 1.24B |
| Investing Cash Flow | -424.20M | -191.70M | -161.60M | -213.90M | -160.40M | -208.00M |
| Financing Cash Flow | -1.00B | -1.21B | -536.70M | -1.59B | -711.90M | -741.90M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $23.00B | 45.27 | 15.71% | ― | 11.42% | 72.60% | |
73 Outperform | $64.08B | 62.38 | 40.20% | ― | 13.99% | -0.95% | |
72 Outperform | $62.34B | 107.97 | 6.66% | ― | 14.21% | -62.56% | |
71 Outperform | $37.00B | 28.20 | 13.80% | 1.09% | 5.22% | 6.27% | |
70 Outperform | $38.55B | 62.82 | ― | ― | 16.66% | 34.26% | |
68 Neutral | $14.86B | 62.55 | 23.69% | 0.56% | 10.45% | -32.43% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
Dassault Systèmes S.A. (ADR) is a leading software company specializing in 3D design, 3D digital mock-up, and product lifecycle management solutions, primarily serving industries such as manufacturing, life sciences, and infrastructure.
Dassault Systèmes S.A. (ADR) recently held its earnings call, revealing a slightly positive sentiment among investors and analysts. The company showcased impressive subscription growth and significant contract wins, particularly in the Industrial segment, which signals a positive trend towards subscription and cloud solutions. However, challenges in the Life Sciences segment, alongside lower growth from MEDIDATA and Centric, as well as concerns regarding cash flow conversion, have tempered the overall enthusiasm.